Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab

Abstract: A 64‐year‐old woman, who had presented with a 30‐year history of refractory asthma, and been treated with anti‐allergic drug therapy, inhaled corticosteroids, a long‐acting beta‐agonist, and a long‐acting muscarinic antagonist. She had been characterized as an allergic, eosinophilic asthmatic. Although omalizumab was tried initially, it was found to be insufficient. We began treatment with benralizumab. The asthma symptom control and sinusitis were improved immediately. Benralizumab was effective for overlapping patient population following negative initial results with omalizumab.

ePDFPDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @EAACI_HQ: Assessing severity of #anaphylaxis: pros and cons of the multiple #anaphylaxis severity-scoring instruments used in literatur…
8hreplyretweetfavorite
Interasma RT @IPCRG: Implementation pack nearly ready. We hope to have it running too! Fantastic experiences to share from Canada, Spain, Portugal…
8hreplyretweetfavorite
Interasma RT @KulikovUNIATF: India’s toxic air claimed 1.24 million lives in 2017, or 12.5% of total deaths recorded that year. #airpolluton #BeatNCD
8hreplyretweetfavorite
Interasma RT @Aller_MD: Epicutaneous immunotherapy in rhino-conjunctivitis and food allergies: a review of the literature https://t.co/4j8S7Ee4p5
8hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma